title: Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup.
abstract: Between 1986 and 1989, 117 patients with pretreatment and serial posttreatment prostate specific antigen values received external beam radiotherapy at our hospital. Followup ranged from 0.6 to 5.9 years (mean 2.7). No patient had hormonal manipulation before distant recurrence. Biochemical relapse, defined as an increasing prostate specific antigen level after treatment, was observed in 44 patients. To date 30 of these 44 patients (68%) have had clinical relapse. The prognostic factors of advanced local stage, high Gleason score and high elevations of pretreatment prostate specific antigen values predicted for biochemical relapse and subsequent clinical failure. The interval between biochemical and clinical relapse was 156 +/- 46 days. Biochemical relapse is an important end point that can be used to determine the effect of treatment in prostatic cancer research.
authors.affiliation: Department of Radiation Oncology, Stanford University Medical Center, California.
authors.forename: I D
authors.initials: ID
authors.lastname: Kaplan
authors.forename: R S
authors.initials: RS
authors.lastname: Cox
authors.forename: M A
authors.initials: MA
authors.lastname: Bagshaw
mesh_terms: D000206:Actuarial Analysis; D000368:Aged; D000369:Aged, 80 and over; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000453:epidemiology; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology / Q000532:radiotherapy*; D011878:Radiotherapy / Q000379:methods; D016896:Treatment Outcome
chemical_list: D017430:Prostate-Specific Antigen